Emergent BioSolutions's total inventories for the quarter that ended in Mar. 2026 was €283.4 Mil. Emergent BioSolutions's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €288.3 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Emergent BioSolutions's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €-6.60.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Emergent BioSolutions's Days Inventory for the
three
months ended in Mar. 2026 was 422.43.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Emergent BioSolutions's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.22.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emergent BioSolutions's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 2.23.
Emergent BioSolutions (STU:ER4) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Emergent BioSolutions's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emergent BioSolutions's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Emergent BioSolutions Total Inventories Related Terms
Emergent BioSolutions Total Inventories Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Emergent BioSolutions (STU:ER4) has a Total Inventories of €283.4 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Total Inventories too high?
Emergent BioSolutions' current Total Inventories is €283.4 Mil. Overall, Emergent BioSolutions has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Total Inventories compare to AQST and EOLS?
Emergent BioSolutions' Total Inventories of €283.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Emergent BioSolutions and its competitors. Emergent BioSolutions's current Total Inventories is €283.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.05, compared to a current price of €7.34 — trading 81.1% above its estimated fair value. The current Total Inventories is €283.4 Mil. Emergent BioSolutions' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Total Inventories is €283.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €7.34 is trading 81.1% above its estimated GF Value™ of €4.05.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
Total Inventories: €283.4 Mil
GF Value™: €4.05 vs. price of €7.34 (81.1% above fair value)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
51GF Score
Get the complete analysis for STU:ER4
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
